NCT03583021View on ClinicalTrials.gov

Sugammadex on Remifentanil Ce for Preventing Emergence Cough in Male

NACompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

June 25, 2018

Primary Completion Date

October 31, 2018

Study Completion Date

December 31, 2018

Conditions
Gallbladder Diseases
Interventions
DRUG

Sugammadex Injectable Product

Sugammadex of 3 mg/kg is injected.

DRUG

Neostigmine Injectable Product

Neostigmine of 50 ug/kg and Glycopyrrolate of 10 ug/kg are injected.

Trial Locations (1)

Unknown

Department of Anesthesiology and Pain Medicine, Ajou University School of Medicine, Suwon

All Listed Sponsors
lead

Ajou University School of Medicine

OTHER

NCT03583021 - Sugammadex on Remifentanil Ce for Preventing Emergence Cough in Male | Biotech Hunter | Biotech Hunter